John McConnell to Prostatic Hyperplasia
This is a "connection" page, showing publications John McConnell has written about Prostatic Hyperplasia.
Connection Strength
0.854
-
McConnell JD, Roehrborn CG, Bautista OM, Andriole GL, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg LM, Clarke HS, Crawford ED, Diokno A, Foley JP, Foster HE, Jacobs SC, Kaplan SA, Kreder KJ, Lieber MM, Lucia MS, Miller GJ, Menon M, Milam DF, Ramsdell JW, Schenkman NS, Slawin KM, Smith JA. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003 Dec 18; 349(25):2387-98.
Score: 0.232
-
Kaplan SA, Roehrborn CG, McConnell JD, Meehan AG, Surynawanshi S, Lee JY, Rotonda J, Kusek JW, Nyberg LM. Long-term treatment with finasteride results in a clinically significant reduction in total prostate volume compared to placebo over the full range of baseline prostate sizes in men enrolled in the MTOPS trial. J Urol. 2008 Sep; 180(3):1030-2; discussion 1032-3.
Score: 0.080
-
Crawford ED, Wilson SS, McConnell JD, Slawin KM, Lieber MC, Smith JA, Meehan AG, Bautista OM, Noble WR, Kusek JW, Nyberg LM, Roehrborn CG. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol. 2006 Apr; 175(4):1422-6; discussion 1426-7.
Score: 0.068
-
Kaplan SA, McConnell JD, Roehrborn CG, Meehan AG, Lee MW, Noble WR, Kusek JW, Nyberg LM. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater. J Urol. 2006 Jan; 175(1):217-20; discussion 220-1.
Score: 0.067
-
Lin VK, Wang SY, Boetticher NC, Vazquez DV, Saboorian H, McConnell JD, Roehrborn CG. Alpha(2) macroglobulin, a PSA binding protein, is expressed in human prostate stroma. Prostate. 2005 May 15; 63(3):299-308.
Score: 0.064
-
Roehrborn CG, Bruskewitz R, Nickel JC, McConnell JD, Saltzman B, Gittelman MC, Malek GH, Gottesman JE, Suryawanshi S, Drisko J, Meehan A, Waldstreicher J. Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia. J Urol. 2004 Mar; 171(3):1194-8.
Score: 0.059
-
Lowe FC, McConnell JD, Hudson PB, Romas NA, Boake R, Lieber M, Elhilali M, Geller J, Imperto-McGinely J, Andriole GL, Bruskewitz RC, Walsh PC, Bartsch G, Nacey JN, Shah S, Pappas F, Ko A, Cook T, Stoner E, Waldstreicher J. Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia. Urology. 2003 Apr; 61(4):791-6.
Score: 0.055
-
Bautista OM, Kusek JW, Nyberg LM, McConnell JD, Bain RP, Miller G, Crawford ED, Kaplan SA, Sihelnik SA, Brawer MK, Lepor H. Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial. Control Clin Trials. 2003 Apr; 24(2):224-43.
Score: 0.055
-
Sherwood JB, McConnell JD, Vazquez DJ, Lin VK, Roehrborn CG. Heterogeneity of 5 alpha-reductase gene expression in benign prostatic hyperplasia. J Urol. 2003 Feb; 169(2):575-9.
Score: 0.055
-
Roehrborn CG, McConnell JD, Saltzman B, Bergner D, Gray T, Narayan P, Cook TJ, Johnson-Levonas AO, Quezada WA, Waldstreicher J. Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes. Eur Urol. 2002 Jul; 42(1):1-6.
Score: 0.052
-
Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, Andriole GL, Geller J, Bracken BR, Tenover JS, Vaughan ED, Pappas F, Taylor A, Binkowitz B, Ng J. The effect of finasteride in men with benign prostatic hyperplasia. 1992. J Urol. 2002 Feb; 167(2 Pt 2):1102-7; discussion 1108.
Score: 0.051
-
Benaim EA, Karam JA, Soboorian MH, Roehrborn CG, McConnell JD, Lin V. The effect of combined androgen ablation on the expression of alpha1A-adrenergic receptor in the human prostate. Prostate. 2004 Sep 01; 60(4):310-6.
Score: 0.015